Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$19.54 - $26.15 $195,400 - $261,500
10,000 Added 98.73%
20,129 $415,000
Q1 2024

May 08, 2024

BUY
$24.75 - $40.66 $247,500 - $406,599
10,000 Added 7751.94%
10,129 $250,000
Q1 2022

Apr 29, 2022

SELL
$30.27 - $49.22 $68,501 - $111,384
-2,263 Reduced 94.61%
129 $5,000
Q3 2021

Oct 12, 2021

SELL
$48.2 - $78.89 $109,028 - $178,449
-2,262 Reduced 48.6%
2,392 $170,000
Q2 2021

Jul 15, 2021

SELL
$21.63 - $57.65 $97,875 - $260,866
-4,525 Reduced 49.3%
4,654 $239,000
Q1 2021

May 03, 2021

SELL
$11.0 - $28.24 $35,002 - $89,859
-3,182 Reduced 25.74%
9,179 $231,000
Q4 2020

Feb 03, 2021

SELL
$10.12 - $13.94 $73,845 - $101,720
-7,297 Reduced 37.12%
12,361 $148,000
Q3 2020

Oct 19, 2020

BUY
$9.93 - $13.47 $15,798 - $21,430
1,591 Added 8.81%
19,658 $196,000
Q1 2020

May 06, 2020

BUY
$7.54 - $15.77 $11,996 - $25,090
1,591 Added 9.66%
18,067 $193,000
Q4 2019

Jan 21, 2020

BUY
$7.48 - $17.01 $21,692 - $49,329
2,900 Added 21.36%
16,476 $261,000
Q3 2019

Nov 06, 2019

BUY
$6.89 - $10.45 $21,703 - $32,917
3,150 Added 30.21%
13,576 $106,000
Q3 2018

Nov 13, 2018

BUY
$12.7 - $15.79 $368 - $457
29 Added 0.28%
10,426 $136,000
Q2 2018

Aug 15, 2018

BUY
$10.99 - $44.21 $35,684 - $143,549
3,247 Added 45.41%
10,397 $152,000
Q1 2018

May 07, 2018

BUY
$27.95 - $45.04 $27,950 - $45,040
1,000 Added 16.26%
7,150 $262,000
Q4 2017

Feb 13, 2018

SELL
$35.44 - $63.76 $109,864 - $197,656
-3,100 Reduced 33.51%
6,150 $231,000
Q3 2017

Nov 14, 2017

BUY
$53.83 - $67.75 $107,660 - $135,500
2,000 Added 27.59%
9,250 $599,000
Q2 2017

Aug 14, 2017

BUY
N/A
7,250
7,250 $392,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $641M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Focused Wealth Management, Inc Portfolio

Follow Focused Wealth Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Focused Wealth Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Focused Wealth Management, Inc with notifications on news.